{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:55:09Z","timestamp":1778853309506,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["843004108"],"award-info":[{"award-number":["843004108"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["10955"],"award-info":[{"award-number":["10955"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>This study aimed to investigate the feasibility and yield of blood sample collection in an investigator-initiated nationwide randomized controlled trial (RCT).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In the PREOPANC-2 trial, 375 patients with (borderline) resectable pancreatic cancer were randomly assigned to two neoadjuvant regiments in 19 centers in the Netherlands (2018\u20132021). Blood sample collection was scheduled at seven time points before, during, and after treatment. The primary outcome was the proportion of successfully collected blood samples at each scheduled time point.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 375 randomized patients, 12 were excluded from blood sample collection before any treatment. From the remaining 363 patients, 1513 (87 %) of 1748 blood samples were collected, processed, mailed, and centrally stored. The blood samples were collected before treatment from 347 (96 %) of the 363 patients, after the first neoadjuvant cycle from 322 (94 %) of 343 patients, after neoadjuvant treatment (i.e., before surgery) from 260 (83 %) of 313 patients, and after surgery from 210 (77 %) of 271 patients. During the follow-up visits, blood samples were collected from 147 (82 %) of 179 patients 12 months after randomization and from 83 (77 %) of 108 patients after 24 months. A total of 220 samples (13 %) were missing. The most common causes for missing blood samples were scheduling oversights, unsuccessful blood draw attempts, and mailing failures (151 times, 69 %). Blood sample collection was canceled 69 times (31 %) due to COVID-19.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Blood sample collection in the PREOPANC-2 trial had a yield of 96 % before treatment and an overall yield of 87 %. Collection of blood samples for biomarker studies is feasible in a nationwide RCT.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1245\/s10434-025-16890-0","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T13:17:42Z","timestamp":1738761462000},"page":"5092-5101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Blood Sample Collection in Randomized Controlled Trials for Biomarker Discovery and Validation: Experience of the PREOPANC-2 Trial"],"prefix":"10.1245","volume":"32","author":[{"given":"Esther N.","family":"Dekker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quisette P.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob L.","family":"van Dam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaby J.","family":"Strijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva M. M.","family":"Verkolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sridhar","family":"Kandala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasper","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amine","family":"Fellah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc G.","family":"Besselink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casper H. J.","family":"van Eijck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolein Y. V.","family":"Homs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert-Jan","family":"van Tienhoven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna W.","family":"Wilmink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana A. M.","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1917-6973","authenticated-orcid":false,"given":"Bas","family":"Groot Koerkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Dutch Pancreatic Cancer Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. V.","family":"Beerepoot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. L.","family":"van Bekkum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. A.","family":"Bonsing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. P.","family":"Bosscha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. A.","family":"Bouwense","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Brouwer-Hol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M. E.","family":"Bruynzeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. R.","family":"Busch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Cirkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. P. L. O.","family":"Coene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. W. B.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. C. M.","family":"Haberkorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. H. J. T.","family":"de Hingh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. M.","family":"Karsten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Kazemier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. B.","family":"van der Kolk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. S. L.","family":"Liem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. J. L.","family":"Loosveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. A. C.","family":"Luelmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. M.","family":"Luyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. S. D.","family":"Mieog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. B.","family":"Nieuwenhuijs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J. M. E.","family":"Nuyttens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"ten Oever","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. A.","family":"Patijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. C.","family":"van Santvoort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. W. J.","family":"Stommel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. M.","family":"Streppel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"ten Tije","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Versteijne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"de Vos - Geelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. F.","family":"de Wilde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"16890_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102019","volume":"86","author":"AM Tsimberidou","year":"2020","unstructured":"Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat Rev. 2020;86:102019.","journal-title":"Cancer Treat Rev."},{"key":"16890_CR2","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrg.2016.86","volume":"17","author":"EA Ashley","year":"2016","unstructured":"Ashley EA. Towards precision medicine. Nat Rev Genet. 2016;17:507\u201322.","journal-title":"Nat Rev Genet."},{"key":"16890_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","volume":"20","author":"E Heitzer","year":"2019","unstructured":"Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20:71\u201388.","journal-title":"Nat Rev Genet."},{"key":"16890_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nrclinonc.2011.121","volume":"8","author":"NB La Thangue","year":"2011","unstructured":"La Thangue NB, Kerr DJ. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol. 2011;8:587\u201396.","journal-title":"Nat Rev Clin Oncol."},{"key":"16890_CR5","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.3390\/cancers12113234","volume":"12","author":"A Khomiak","year":"2020","unstructured":"Khomiak A, Brunner M, Kordes M, Lindblad S, Miksch RC, \u00d6hlund D, Regel I. Recent discoveries of diagnostic, prognostic, and predictive biomarkers for pancreatic cancer. Cancers. 2020;12:3234.","journal-title":"Cancers."},{"key":"16890_CR6","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","volume":"66","author":"A Li\u00e8vre","year":"2006","unstructured":"Li\u00e8vre A, Bachet J-B, Le Corre D, Boige V, Landi B, Emile J-F, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992\u20135.","journal-title":"Cancer Res."},{"key":"16890_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3390\/cells9010219","volume":"9","author":"N Garcia-Carbonero","year":"2020","unstructured":"Garcia-Carbonero N, Martinez-Useros J, Li W, Orta A, Perez N, Carames C, et al. KRAS and BRAF mutations as prognostic and predictive biomarkers for standard chemotherapy response in metastatic colorectal cancer: a single-institutional study. Cells. 2020;9:219.","journal-title":"Cells."},{"key":"16890_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ejca.2022.12.024","volume":"181","author":"CWF van Eijck","year":"2023","unstructured":"van Eijck CWF, de Koning W, van der Sijde F, Moskie M, Koerkamp BG, Homs MYV, et al. A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma. Eur J Cancer. 2023;181:119\u201334.","journal-title":"Eur J Cancer."},{"key":"16890_CR9","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1200\/JCO.22.02668","volume":"42","author":"R Nicolle","year":"2024","unstructured":"Nicolle R, Bachet J-B, Harl\u00e9 A, Iovanna J, Hammel P, Rebours V, et al. Prediction of adjuvant gemcitabine sensitivity in resectable pancreatic adenocarcinoma using the GemPred RNA signature: an ancillary study of the PRODIGE-24\/CCTG PA6 clinical trial. J Clin Oncol. 2024;42:1067\u201376.","journal-title":"J Clin Oncol."},{"key":"16890_CR10","doi-asserted-by":"publisher","first-page":"5115","DOI":"10.1158\/1078-0432.CCR-22-2576","volume":"28","author":"S Perera","year":"2022","unstructured":"Perera S, Jang GH, Wang Y, Kelly D, Allen M, Zhang A, et al. hENT1 expression predicts response to gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma. Clin Cancer Res. 2022;28:5115\u201320.","journal-title":"Clin Cancer Res."},{"key":"16890_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/cancers11010093","volume":"11","author":"F van der Sijde","year":"2019","unstructured":"van der Sijde F, Vietsch EE, Mustafa DAM, Besselink MG, Groot Koerkamp B, van Eijck CHJ. Circulating biomarkers for prediction of objective response to chemotherapy in pancreatic cancer patients. Cancers. 2019;11:93.","journal-title":"Cancers."},{"key":"16890_CR12","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1200\/JCO.2009.22.3701","volume":"27","author":"SJ Mandrekar","year":"2009","unstructured":"Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol. 2009;27:4027.","journal-title":"J Clin Oncol."},{"key":"16890_CR13","unstructured":"Network TNCC. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Pancreatic adenocarcinoma (Version 1.2024) 2024 [updated December 13, 2023. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf."},{"key":"16890_CR14","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1016\/S1470-2045(22)00059-6","volume":"23","author":"R Coleman","year":"2022","unstructured":"Coleman R, Chan A, Barrios C, Cameron D, Costa L, Dowsett M, et al. Code of practice needed for samples donated by trial participants. Lancet Oncol. 2022;23:e89\u201390.","journal-title":"Lancet Oncol."},{"key":"16890_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-021-08031-z","volume":"21","author":"QP Janssen","year":"2021","unstructured":"Janssen QP, van Dam JL, Bonsing BA, Bos H, Bosscha KP, Coene P, et al. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer. 2021;21:1\u20138.","journal-title":"BMC Cancer."},{"key":"16890_CR16","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.2013.53.8009","volume":"32","author":"LM Ellis","year":"2014","unstructured":"Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014;32:1277\u201380.","journal-title":"J Clin Oncol."},{"key":"16890_CR17","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011\u201324.","journal-title":"Lancet."},{"key":"16890_CR18","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395\u2013406.","journal-title":"N Engl J Med."},{"key":"16890_CR19","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jama.2010.1275","volume":"304","author":"JP Neoptolemos","year":"2010","unstructured":"Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073\u201381.","journal-title":"JAMA."},{"key":"16890_CR20","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med."},{"issue":"4_suppl","key":"16890_CR21","doi-asserted-by":"publisher","first-page":"TPS635","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS635","volume":"40","author":"JJ Knox","year":"2022","unstructured":"Knox JJ, Jaffee EM, O\u2019Kane GM, Plenker D, Zhang A, Ramotar S, et al. PASS-01: pancreatic adenocarcinoma signature stratification for treatment\u201301. Am Soc Clin Oncol. 2022;40(4_suppl):TPS635.","journal-title":"Am Soc Clin Oncol."},{"key":"16890_CR22","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1200\/JCO.2014.56.2561","volume":"32","author":"JB Smerage","year":"2014","unstructured":"Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 2014;32:3483.","journal-title":"J Clin Oncol."},{"key":"16890_CR23","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1001\/jama.2021.2454","volume":"325","author":"JA Meyerhardt","year":"2021","unstructured":"Meyerhardt JA, Shi Q, Fuchs CS, Meyer J, Niedzwiecki D, Zemla T, et al. Effect of celecoxib vs placebo added to standard adjuvant therapy on disease-free survival among patients with stage III colon cancer: the CALGB\/SWOG 80702 (Alliance) randomized clinical trial. JAMA. 2021;325:1277\u201386.","journal-title":"JAMA."},{"key":"16890_CR24","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239\u201346.","journal-title":"Lancet Oncol."},{"key":"16890_CR25","unstructured":"National Comprehensive Cancer N. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer, Version 4; 2024. National Comprehensive Cancer Network, Inc, Fort Washington, PA; 2024."},{"key":"16890_CR26","doi-asserted-by":"crossref","unstructured":"Groot Koerkamp B. Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): a multicenter randomized controlled trial. ESMO Conference; Madrid, Spain2023.","DOI":"10.1016\/j.annonc.2023.10.084"},{"key":"16890_CR27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1158\/1535-7163.MCT-17-1298","volume":"18","author":"T Wei","year":"2019","unstructured":"Wei T, Zhang Q, Li X, Su W, Li G, Ma T, et al. Monitoring tumor burden in response to FOLFIRINOX chemotherapy via profiling circulating cell-free DNA in pancreatic cancer. Mol Cancer Ther. 2019;18:196\u2013203.","journal-title":"Mol Cancer Ther."},{"key":"16890_CR28","doi-asserted-by":"publisher","first-page":"175883592110337","DOI":"10.1177\/17588359211033704","volume":"13","author":"F van der Sijde","year":"2021","unstructured":"van der Sijde F, Azmani Z, Besselink MG, Bonsing BA, de Groot JWB, Groot Koerkamp B, et al. Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX. Ther Adv Med Oncol. 2021;13:17588359211033704.","journal-title":"Ther Adv Med Oncol."},{"key":"16890_CR29","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-22-3089","volume":"29","author":"BL Ecker","year":"2023","unstructured":"Ecker BL, Tao AJ, Janssen QP, Walch HS, Court CM, Balachandran VP, et al. Genomic biomarkers associated with response to induction chemotherapy in patients with localized pancreatic ductal adenocarcinoma. Clin Cancer Res. 2023;29:1368\u201374.","journal-title":"Clin Cancer Res."},{"key":"16890_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.100975","volume":"49","author":"CWF van Eijck","year":"2024","unstructured":"van Eijck CWF, Sabroso-Lasa S, Strijk GJ, Mustafa DAM, Fellah A, Koerkamp BG, et al. A liquid biomarker signature of inflammatory proteins accurately predicts early pancreatic cancer progression during FOLFIRINOX chemotherapy. Neoplasia. 2024;49:100975.","journal-title":"Neoplasia."},{"key":"16890_CR31","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1097\/SLA.0000000000003084","volume":"271","author":"LL Meijer","year":"2020","unstructured":"Meijer LL, Garajov\u00e1 I, Caparello C, Le Large TYS, Frampton AE, Vasile E, et al. Plasma miR-181a-5p downregulation predicts response and improved survival after FOLFIRINOX in pancreatic ductal adenocarcinoma. Ann Surg. 2020;271:1137\u201347.","journal-title":"Ann Surg."},{"issue":"12","key":"16890_CR32","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1038\/s41416-022-01745-2","volume":"126","author":"D Pietrasz","year":"2022","unstructured":"Pietrasz D, Sereni E, Lancelotti F, Pea A, Luchini C, Innamorati G, et al. Circulating tumour DNA: a challenging innovation to develop \u201cprecision onco-surgery\u201d in pancreatic adenocarcinoma. Br J Cancer. 2022;126(12):1676\u201383.","journal-title":"Br J Cancer."},{"key":"16890_CR33","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/annonc\/mdz200","volume":"30","author":"B Lee","year":"2019","unstructured":"Lee B, Lipton L, Cohen J, Tie J, Javed AA, Li L, et al. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Ann Oncol. 2019;30:1472\u20138.","journal-title":"Ann Oncol."},{"issue":"3","key":"16890_CR34","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41591-023-02790-x","volume":"30","author":"L Jiang","year":"2024","unstructured":"Jiang L, Qin J, Dai Y, Zhao S, Zhan Q, Cui P, et al. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. Nat Med. 2024;30(3):749\u201361.","journal-title":"Nat Med."},{"key":"16890_CR35","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.3390\/ijms25031640","volume":"25","author":"E Ram\u00edrez-Maldonado","year":"2024","unstructured":"Ram\u00edrez-Maldonado E, L\u00f3pez Gordo S, Major Branco RP, Pavel M-C, Estalella L, Ll\u00e0cer-Mill\u00e1n E, et al. Clinical application of liquid biopsy in pancreatic cancer: a narrative review. Int J Mol Sci. 2024;25:1640.","journal-title":"Int J Mol Sci."},{"key":"16890_CR36","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1158\/1078-0432.CCR-19-0197","volume":"25","author":"VP Groot","year":"2019","unstructured":"Groot VP, Mosier S, Javed AA, Teinor JA, Gemenetzis G, Ding D, et al. Circulating tumor DNA as a clinical test in resected pancreatic cancer molecular relapse of PDAC. Clin Cancer Res. 2019;25:4973\u201384.","journal-title":"Clin Cancer Res."},{"key":"16890_CR37","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/PPO.0b013e3181bd0445","volume":"15","author":"DSW Tan","year":"2009","unstructured":"Tan DSW, Thomas GV, Garrett MD, Banerji U, De Bono JS, Kaye SB, Workman P. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J. 2009;15:406\u201320.","journal-title":"Cancer J."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-16890-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-16890-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-16890-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T12:57:32Z","timestamp":1748869052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-16890-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["16890"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-16890-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Eileen M. O\u2019Reilly received research funding for the institution from Genentech\/Roche, BioNTech, AstraZeneca, Arcus, Elicio, Parker Institute, NIH\/NCI, and Digestive Care. She is consulting\/DSMB for Arcus, Ability Pharma, Alligator Bioscience, BioNTech, Ipsen, Merck, Novartis, Syros, Leap Therapeutics, Astellas, Autem, BMS, Revolution Medicine, Tempus, Fibrogen, Merus, Revi Agios (spouse), Genentech-Roche (spouse), Eisai (spouse), and Servier (Spouse). Johanna W. Wilmink is consulting\/advisor for MSD, Servier, Novartis, Astra Zeneca, and Nordic. She has received research funding for the institution from Servier, Nordic, and MSD. Casper H. J. van Eijck is consultant for AIM ImunnoTech. The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}